Phase 2 trial results of lixisenatide published
The full results of the one-year, phase 2 clinical trial of Type 2 diabetes drug lixisenatide have now been published. This Cure Parkinson’s co-funded trial has reported positive results, indicating that the treatment may slow the progression of motor symptoms. Researchers have reported that the...
Learn more
International Women’s Day and Parkinson’s
On 8 March, we celebrate International Women’s Day by shining a light on the work of female researchers and scientists who have made significant contributions to the Parkinson’s community, and the impact of their work in advancing our understanding of the role of sex and…
Cure Parkinson’s Fundraising Heroes: February 2024
February’s fundraising heroes have all taken on long term fundraising events to support our research. An untraditional triathlon Fundraising heroes Phil and Sue created their own triathlon-inspired challenge to raise funds for our research following Phil’s Parkinson’s diagnosis and to mark Sue’s 70th birthday. They…
The Power of HIIT for Parkinson’s
A small pilot study has found that high-intensity interval training – or HIIT – can have positive effects for people with Parkinson’s, both on overall well-being and potentially on brain chemistry.
Latest updates in the field of neurotrophic factors in Parkinson’s
Neurotrophic factors such as GDNF are still being actively investigated as a potential treatment for Parkinson’s, and alternative methods of delivery are currently being explored.
Phase 2 clinical trial of dapansutrile for Parkinson’s confirmed
Cure Parkinson’s, in partnership with Van Andel Institute, is delighted to announce funding for a Phase 2 clinical of dapansutrile, an anti-inflammatory drug, to determine whether it can slow the progression of Parkinson’s.